COMMUNIQUÉS West-GlobeNewswire

-
Nicox : Prolongation de 5 ans de la durée d’un brevet américain couvrant le latanoprostene bunod commercialisé sous le nom de VYZULTA®
31/01/2024 -
ANeuroTech publishes Phase IIIa data for ANT-01, an adjunctive anti-depression drug, in Personalized Medicine in Psychiatry
31/01/2024 -
Geneva Court Grants Temporary Moratorium to ObsEva
31/01/2024 -
Addex Enters into At-The-Market ADS Offering Agreement with H.C. Wainwright & Co. LLC.
31/01/2024 -
Sandoz launches first and only biosimilar for multiple sclerosis, Tyruko® (natalizumab), in Germany
31/01/2024 -
Novartis delivers strong full year performance, 10% net sales and 18% core operating income growth (cc¹), with margin expansion. Continuing innovation momentum with multiple positive Ph3 readouts
31/01/2024 -
Novartis : forte performance en 2023, hausse de 10 % du chiffre d’affaires net et de 18 % du résultat opérationnel core (tcc¹), expansion de la marge. Innovation : nombreux résultats positifs de phase III
31/01/2024 -
Vaxcyte Announces Pricing of $750 Million Public Offering
31/01/2024 -
Immunocore Prices Upsized Convertible Senior Notes Offering
31/01/2024 -
BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting
31/01/2024 -
23andMe Launches Month-Long Initiative to Amplify ARRAY’s “Seat16” Program for Acclaimed Film ORIGIN by Ava DuVernay
31/01/2024 -
Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2023
31/01/2024 -
IBA SA – NOTIFICATION TRANSPARENCE
31/01/2024 -
IBA – TRANSPARENCY NOTIFICATION
31/01/2024 -
Corbus Pharmaceuticals Announces Proposed Public Offering
31/01/2024 -
Guardion Health Sciences Announces Entry into Definitive Agreement to Sell its Well-Known Viactiv® Brand and Business to Doctor’s Best Inc.
31/01/2024 -
Trinity Biotech plc to Host Investor Call
30/01/2024 -
Investors and Innovators Representing more than $309B in Biotech Assets and 624 New Drugs in Development Urge the Congressional Budget Office to Update its Drug R&D Policy Impact Model
30/01/2024 -
Myriad Genetics Names George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology
30/01/2024
Pages